summary: Natalizumab is one of the current options for treatment in MS. It is thought that Natalizumab exerts its therapeutic efficacy by blocking the pass of T cells, a specific immune cell which plays a major role in the pathogenesis of MS, through the blood brain barrier, thus preventing these cells reaching the central nervous system. The authors of this study have investigated the immunological effects of Natalizumab in an animal model of MS and have provided for the first time in vivo evidence of this blockage.

authors: Coisne C, Mao W, Engelhardt B

source: J Immunol. 2009 May 15;182(10):5909-13

weblink: click here

category: Immunology
category: Clinical Trials and Therapeutics

related research news: click here

glossary: